Journal Article
. 2019 Oct;6(3).
doi: 10.1001/jamaoncol.2019.4794.

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial

Joseph A Sparano 1 Robert J Gray 2 Della F Makower 1 Kathy S Albain 3 Thomas J Saphner 4 Sunil S Badve 5 Lynne I Wagner 6 Virginia G Kaklamani 6 Maccon M Keane 7 Henry L Gomez 8 Pavan S Reddy 9 Timothy F Goggins 10 Ingrid A Mayer 11 Deborah L Toppmeyer 12 Adam M Brufsky 13 Matthew P Goetz 14 Jeffrey L Berenberg 15 Catalin Mahalcioiu 16 Christine Desbiens 17 Daniel F Hayes 18 Elizabeth C Dees 19 Charles E Geyer 20 John A Olson 21 William C Wood 22 Tracy Lively 23 Soonmyung Paik 24 Matthew J Ellis 25 Jeffrey Abrams 23 George W Sledge 26 
Affiliations
  • PMID: 31566680
  •     13 citations

Abstract

Importance: A high 21-gene recurrence score (RS) by breast cancer assay is prognostic for distant recurrence of early breast cancer after local therapy and endocrine therapy alone, and for chemotherapy benefit.

Objective: To describe clinical outcomes for women with a high RS who received adjuvant chemotherapy plus endocrine therapy in the TAILORx trial, a population expected to have a high distant recurrence rate with endocrine therapy alone.

Design, Setting, And Participants: In this secondary analysis of data from a multicenter randomized clinical trial, 1389 women with hormone receptor-positive, ERBB2-negative, axillary node-negative breast cancer, and a high RS of 26 to 100 were prospectively assigned to receive adjuvant chemotherapy in addition to endocrine therapy. The analysis was conducted on May 12, 2019.

Interventions: The adjuvant chemotherapy regimen was selected by the treating physician.

Main Outcomes And Measures: Freedom from recurrence of breast cancer at a distant site, and freedom from recurrence, second primary cancer, and death (also known as invasive disease-free survival [IDFS]).

Results: Among the 9719 eligible women, with a mean age of 56 years (range 23-75 years), 1389 (14%) had a recurrence score of 26 to 100, of whom 598 (42%) had an RS of 26 to 30 and 791 (58%) had an RS of 31 to 100. The most common chemotherapy regimens included docetaxel/cyclophosphamide in 589 (42%), an anthracycline without a taxane in 334 (24%), an anthracycline and taxane in 244 (18%), cyclophosphamide/methotrexate/5-fluorouracil in 52 (4%), other regimens in 81 (6%), and no chemotherapy in 89 (6%). At 5 years, the estimated rate of freedom from recurrence of breast cancer at a distant site was 93.0% (standard error [SE], 0.8%), freedom of recurrence of breast cancer at a distant and/or local regional site 91.0% (SE, 0.8%), IDFS 87.6% (SE, 1.0%), and overall survival 95.9% (SE, 0.6%).

Conclusions And Relevance: The estimated rate of freedom from recurrence of breast cancer at a distant site in women with an RS of 26 to 100 treated largely with taxane and/or anthracycline-containing adjuvant chemotherapy regimens plus endocrine therapy in the prospective TAILORx trial was 93% at 5 years, an outcome better than expected with endocrine therapy alone in this population.

Trial Registration: ClinicalTrials.gov identifier: NCT00310180.

Association of Adjuvant Chemotherapy With Overall Survival in Patients With Early-Stage Breast Cancer and 21-Gene Recurrence Scores of 26 or Higher.
Sung Jun Ma, Oluwadamilola T Oladeru, Anurag K Singh.
JAMA Netw Open, 2020 May 05; 3(5). PMID: 32364592    Free PMC article.
Management of hormone receptor-positive, HER2-negative early breast cancer.
Elaine M Walsh, Karen L Smith, Vered Stearns.
Semin Oncol, 2020 Jun 18; 47(4). PMID: 32546323    Free PMC article.
Review.
Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30.
Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen.
Oncol Lett, 2020 Jul 30; 20(2). PMID: 32724396    Free PMC article.
The 21-Gene Recurrence Score Assay and Prediction of Chemotherapy Benefit: A Propensity Score-Matched Analysis of the SEER Database.
In Sil Choi, Jiwoong Jung, +5 authors, Ki-Tae Hwang.
Cancers (Basel), 2020 Jul 12; 12(7). PMID: 32650374    Free PMC article.
Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer.
Rocío Núñez-Torres, Miguel Martín, +11 authors, Anna González-Neira.
JAMA Dermatol, 2020 Aug 07; 156(9). PMID: 32756886    Free PMC article.
The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[18F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review.
John A Katzenellenbogen.
Nucl Med Biol, 2020 Apr 02;. PMID: 32229068    Free PMC article.
Review.
PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging.
John A Katzenellenbogen.
Cancers (Basel), 2020 Jul 29; 12(8). PMID: 32718075    Free PMC article.
Review.
Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test.
Debbie M Jakubowski, Helen Bailey, +7 authors, Frederick L Baehner.
J Surg Oncol, 2020 Jun 05;. PMID: 32497318    Free PMC article.
Future perspectives of surgical treatment of breast cancer.
Margit Riis.
Ann Med Surg (Lond), 2020 Oct 03; 59. PMID: 33005399    Free PMC article.
Effect of an Artificial Intelligence Clinical Decision Support System on Treatment Decisions for Complex Breast Cancer.
Fengrui Xu, Martín-J Sepúlveda, +13 authors, Kyu Rhee.
JCO Clin Cancer Inform, 2020 Sep 25; 4. PMID: 32970484    Free PMC article.
Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment.
Arthur Foulon, Pierrick Theret, Lise Rodat-Despoix, Philippe Kischel.
Cancers (Basel), 2020 Sep 20; 12(9). PMID: 32947780    Free PMC article.
Review.
Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database.
Ran Cheng, Xiangyi Kong, +2 authors, Jing Wang.
Front Oncol, 2020 Nov 17; 10. PMID: 33194568    Free PMC article.
How to Predict Metastasis in Luminal Breast Cancer? Current Solutions and Future Prospects.
Sylwia Tabor, Małgorzata Szostakowska-Rodzos, Anna Fabisiewicz, Ewa A Grzybowska.
Int J Mol Sci, 2020 Nov 14; 21(21). PMID: 33182512    Free PMC article.
Review.